ANTI-IL4 RECEPTOR ANTIBODIES FOR VETERINARY USE

• Main Authors: ZHAN HANGJUN, NGUYEN LAM, RICHARD CHIN, SHYR JIANN LI
• Format: Patent
• Language: English; Japanese
• Published: 23.01.2024
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; VINEGAR; WINE

To provide methods and compounds that can be used specifically to block companion animal IL4 or/and IL13 for treating IL4-induced and/or IL 13-induced conditions and for reducing IL4/IL13 signaling.SOLUTION: Provided are various embodiments relating to anti-IL4R antibodies that bind to canine IL4R. In various embodiments, such anti-IL4R antibodies can be used in methods to treat IL4/IL13-induced conditions, such as atopic dermatitis, allergic dermatitis, pruritus, asthma, psoriasis, scleroderma and eczema, in companion animals, such as canines and felines. Also provided are various embodiments relating to variant IgG Fc polypeptides and variant light chain constant regions of companion animal species for the preparation of antibodies or bispecific antibodies.SELECTED DRAWING: None 【課題】ＩＬ４誘導性及び／又はＩＬ１３誘導性状態を治療するため、及びＩＬ４／ＩＬ１３シグナル伝達を低減させるために、コンパニオンアニマルＩＬ４又は／及びＩＬ１３をブロックするために特異的に使用することができる方法及び化合物を提供する。【解決手段】イヌＩＬ４Ｒに結合する抗ＩＬ４Ｒ抗体に関する様々な実施態様が提供される。様々な実施態様において、そのような抗ＩＬ４Ｒ抗体は、イヌ及びネコなどのコンパニオンアニマルにおいて、アトピー性皮膚炎、アレルギー性皮膚炎、そう痒症、喘息、乾癬、強皮症、及び湿疹などのＩＬ４／ＩＬ１３誘導性状態を治療する方法において使用することができる。抗体又は二重特異性抗体の調製のための、コンパニオンアニマル種の変異体ＩｇＧ Ｆｃポリペプチド及び変異体軽鎖定常領域に関する様々な実施態様も提供される。【選択図】なし